Resources
National Fetal Alcohol Spectrum Disorder (FASD) Strategic Action Plan 2018-2028 – Three-year implementation review
This report shares review findings of the National Fetal Alcohol Spectrum Disorder (FASD) Strategic Action Plan 2018-2028 implementation. The review’s aim is to inform the Australian Government if the plan is on-track to achieving its goals.
Life Saving Drugs Program – Fact sheet for patients
Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement
This document states the outcome of Sanofi-Aventis Australia's application to include eliglustat on the Life Saving Drugs Program.
Life Saving Drugs Program – Fact sheet for treating physicians
This fact sheet gives answers to common questions about the role of treating physicians in prescribing Life Saving Drugs Program (LSDP) medicines.
Life Saving Drugs Program – Change of treating physician form
Use this form to help transition a patient’s care to a new physician, where there are no other changes to their treatment or eligibility for the Life Saving Drugs Program (LSDP).
Life Saving Drugs Program – Sebelipase alfa (Kanuma®) outcome statement
Summary of the consideration of the application from Alexion Australia for the inclusion of sebelipase alfa (Kanuma®) on the LSDP for the treatment of infantile onset lysosomal acid lipase deficiency (LAL-D).
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 26 May 2023
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 15th meeting on 26 May 2023.
National Site of Recognition Steering Committee communique – 2 March 2023
Details of the forth meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 2 March 2023.
Life Saving Drugs Program – PNH – Review summary and Expert Panel recommendations
This PNH review considered eculizumab. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – PNH – Review summary and Expert Panel recommendations for consumers
This PNH review considered eculizumab. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – HT1 – Review summary and Expert Panel recommendations
This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – HT1 – Review summary and Expert Panel recommendations for consumers
This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – Gaucher disease – Review summary and expert panel recommendations for consumers
This Gaucher disease review considered 3 enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health.
Life Saving Drugs Program – MPS II – Review summary and expert panel recommendations
This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – MPS II – Review summary and expert panel recommendations for consumers
This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – Pompe disease – Review summary and expert panel recommendations
This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – Pompe disease – Review summary and expert panel recommendations for consumers
This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – Gaucher disease – Review summary and expert panel recommendations
This Gaucher disease review considered three enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – Fact sheet for pharmacists
This fact sheet gives answers to common questions about the role of pharmacies and authorised persons in managing Life Saving Drugs Program (LSDP) medicines.
Life Saving Drugs Program – MPS I – Review summary and expert panel recommendations for consumers
This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Life Saving Drugs Program – MPS I – Review summary and expert panel recommendations
This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.
Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers
This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer
Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations
This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 17 February 2023
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 14th meeting on 17 February 2023.
healthdirect symptom checker
Use this tool if you’re feeling unwell and not sure what to do – if it’s an emergency, call 000 immediately. Answer some questions about your symptoms and get advice on whether to see a doctor, go to hospital or call an ambulance. It is available online at any time.
Date last updated: